Healthpeak Secures $400M Credit Facility Following Janus Living IPO Spinoff
Healthpeak Properties (NYSE: DOC) secured a new $400 million delayed draw term loan facility and expanded its total borrowing capacity to $2 billion on March 23, 2026, moves that coincided with the successful initial public offering of its spinoff Janus Living.
The Deal
The healthcare REIT executed three credit agreement amendments simultaneously with the closing of Janus Living's IPO. The centerpiece was a new $400 million senior unsecured delayed draw term loan facility with a five-year maturity, providing Healthpeak with significant financial flexibility following the spinoff transaction.
The new facility carries competitive pricing with interest rates based on the company's debt ratings. Initial margins are set at 0.00% for base rate loans and 0.80% for SOFR-based loans, with the potential to adjust based on Healthpeak's credit profile. The facility uses either Term SOFR or Daily SOFR as its benchmark rate, with a 0% floor, reflecting current market standards for investment-grade borrowers.
Beyond the new facility, Healthpeak increased its maximum aggregate borrowing capacity under its existing term loan agreement from $1.5 billion to $2.0 billion. This expansion leaves the company with $750 million in unused borrowing capacity, providing a substantial financial cushion for future growth initiatives or market opportunities.
Strategic Rationale
The timing of these credit enhancements appears carefully orchestrated to coincide with the Janus Living spinoff, suggesting Healthpeak's management anticipated potential capital needs following the separation. By securing these facilities concurrent with the IPO, Healthpeak ensures it maintains strong liquidity despite the departure of Janus Living's assets and cash flows.
The expanded credit capacity positions Healthpeak to pursue acquisitions or development opportunities in its core healthcare real estate segments. With $750 million in undrawn capacity plus the $400 million delayed draw facility, the REIT has access to over $1.1 billion in liquidity without tapping equity markets.
The structure as a delayed draw term loan is particularly strategic, allowing Healthpeak to secure favorable terms now without immediately incurring interest expense. The company can draw on these funds as needed over the facility's life, providing flexibility to time investments with market opportunities.
Importantly, the amendments received full lender consent for the Janus Living IPO and related transactions, eliminating any covenant concerns around the spinoff. Neither the revolving credit facility nor the Physicians Realty term loan saw changes to their maturity dates, pricing, or outstanding amounts, maintaining stability in Healthpeak's existing debt structure.
What to Watch
Investors should monitor how quickly Healthpeak deploys its expanded credit capacity. The timing and nature of any drawdowns on the new facility will signal management's view on acquisition opportunities in the healthcare real estate market and their capital allocation priorities post-spinoff.
The company's debt ratings will be crucial to watch, as they directly impact borrowing costs under the new facility. Any ratings changes could adjust the applicable margins by up to 75 basis points, potentially affecting Healthpeak's cost of capital and competitive position.
The success of the Janus Living IPO and its subsequent trading performance may also influence market perception of Healthpeak's remaining portfolio. A strong performance by Janus could validate the spinoff strategy and potentially unlock value in Healthpeak's shares.
With healthcare REITs facing an evolving landscape of demographic tailwinds but operational challenges, Healthpeak's enhanced financial flexibility provides important optionality. The company can now pursue opportunistic acquisitions, fund development projects, or simply maintain a strong balance sheet through market volatility.
The five-year maturity on the new facility aligns well with typical real estate investment horizons, giving management ample time to execute on strategic initiatives without near-term refinancing pressure. This patient capital structure should support Healthpeak's ability to create long-term shareholder value in the post-spinoff era.